Table 2.

Ongoing Clinical Trials of Potential Immunotherapy Approaches of Esophageal Adenocarcinoma or Esophageal-Squamous-Cell-Carcinoma (EAC/ESCC) Patients.

Target	Drug	Cancer Type	Intervention/Treatment	Clinical Phase	Clinical Trials.gov	Status
PD-1 inhibitors	Pembrolizumab	previously treated advanced G/GEJ with PD-L1 CPS ≥ 1	Pembrolizumab or placebo Plus Chemotherapy (XP or FP)	III	NCT03221426	Recruiting
	Pembrolizumab	patients with potentially resectable G/GEJ	mFOLFOX6 +Pembrolizumab	II	NCT03488667	Recruiting
	Pembrolizumab	metastatic gastroesophageal cancer	lenvatinib and pemrolizumab	II	NCT03321630	Recruiting
	Nivolumab	advanced G/GEJC	BMS-986213 (Relatlimab and or Nivolumab) or Nivolumab only + investigator's choice chemotherapy (XELOX or FOLFOX or SOX)	II	NCT03662659	Recruiting
	Nivolumab	advanced or metastatic EGA	ipilimumab or 5-FU/folinic acid and oxaliplatin (FOLFOX) in combination with nivolumab and trastuzumab	II	NCT03409848	Recruiting
	Nivolumab	pStage III G/GEJC after D2 or more extensive lymph node dissection	Nivolumab or placebo + S-1 or CapeOX	III	NCT03006705	Recruiting
	Camrelizumab	unresectable recurrent or metastatic Alpha-fetoprotein (AFP)-Producing G/GEJC	Cohort 1:camrelizumab and apatinib+SOX(as first-line therapy)Cohort 2:camrelizumab and apatinib (≥ 1 line)	II	NCT04609176	Recruiting
PD-L1 inhibitors	Avelumab	Her2(-), locally advanced or metastatic GC or GEJC	Avelumab maintenance versus continued chemotherapy after 12 wk of first-line induction chemotherapy	III	NCT02625610	Recruiting
	Avelumab	Resectable G/GEJC	avelumab+FLOT (4 cycles previous to surgery + 4 cycles of adjuvant therapy, avelumab up to one year	II	NCT03979131	Recruiting
	Atezolizumab	Nonmetastatic, Resectable Gastric, and GE-junction Cancer	Atezolizumab+ chemotherapy(capecitabine, oxaliplatin and docetaxel)	II	NCT 03448835	Recruiting
	Atezolizumab	Operable oesophageal and GC	Atezolizumab+ FLOT	II	NCT03399071	Recruiting
	Atezolizumab	locally advanced, operable adenocarcinoma of the stomach or GEJ.	Atezolizumab+ FLOT versus FLOT alone	II	NCT03421288	Active, not recruiting
	Durvalumab	Resectable GC/GEJCancer	Durvalumab or placebo combined with FLOT chemotherapy	III	NCT04592913	Recruiting
	Nivolumab + ipilimumab	advanced GC	Nivolumab + ipilimumab versus Nivolumab +relatlimab versus Nivolumab + BMS-986 205 versus Nivo +rucaparib versus ipilimumab + rucaparib versus Nivolumab + ipilimumab + rucaparib	II	NCT02935634	Recruiting